Literature DB >> 12668355

Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain.

Gavin P Reynolds1, ZhiJun Zhang, XiaoBin Zhang.   

Abstract

OBJECTIVE: Weight gain, leading to further morbidity and poor treatment adherence, is a common consequence of treatment with antipsychotic drugs. A recent study showed that a polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene is associated with antipsychotic-induced weight gain. The authors determined whether this association held true for weight gain after clozapine treatment.
METHOD: Thirty-two Chinese Han patients with first-episode schizophrenia were genotyped for the -759C/T polymorphism and had weight changes monitored after 6 weeks of clozapine treatment.
RESULTS: The authors found that the 10 patients with the -759T variant allele showed significantly less weight gain than those without this allele. The effect was strongest in the male patients and not apparent in the female patients.
CONCLUSIONS: These findings identify an important genetic factor associated with clozapine-induced weight increases in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12668355     DOI: 10.1176/appi.ajp.160.4.677

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  36 in total

Review 1.  Gene-environment interplay in schizopsychotic disorders.

Authors:  Tomas Palomo; Trevor Archer; Richard M Kostrzewa; Rrichard J Beninger
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 2.  Pharmacogenetics of antipsychotic-induced weight gain.

Authors:  Christoph U Correll; Anil K Malhotra
Journal:  Psychopharmacology (Berl)       Date:  2004-07-08       Impact factor: 4.530

Review 3.  Pharmacogenetics and psychiatry.

Authors:  Amlan Basu; Eva Tsapakis; Kathy Aitchison
Journal:  Curr Psychiatry Rep       Date:  2004-04       Impact factor: 5.285

Review 4.  Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.

Authors:  Jian-Ping Zhang; Anil K Malhotra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-01       Impact factor: 4.481

Review 5.  Genetics and psychopharmacology: prospects for individualized treatment.

Authors:  Charles U Nnadi; Joseph F Goldberg; Anil K Malhotra
Journal:  Essent Psychopharmacol       Date:  2005

Review 6.  A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment.

Authors:  Jose M Palacios; Angel Pazos; Daniel Hoyer
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

7.  Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment.

Authors:  D F Heitjan; D A Asch; Riju Ray; Margaret Rukstalis; Freda Patterson; C Lerman
Journal:  Pharmacogenomics J       Date:  2008-03-18       Impact factor: 3.550

Review 8.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

Review 9.  Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.

Authors:  Marc De Hert; Weiping Yu; Johan Detraux; Kim Sweers; Ruud van Winkel; Christoph U Correll
Journal:  CNS Drugs       Date:  2012-09-01       Impact factor: 5.749

Review 10.  [Genetics of weight gain associated with antipsychotic medications].

Authors:  D J Müller; C Peter; I Puls; E J Brandl; U E Lang; J Gallinat; A Heinz
Journal:  Nervenarzt       Date:  2009-05       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.